Document Detail


Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants.
MedLine Citation:
PMID:  10796379     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: This section is under preparation and will be included in the next issue.
OBJECTIVES: To compare the effect of prophylactic surfactant administration to surfactant treatment of established respiratory distress syndrome in premature infants.
SEARCH STRATEGY: Searches were made of the Oxford Database of Perinatal Trials, Medline (MeSH terms: pulmonary surfactant; limits: age groups, newborn infants), previous reviews including cross-references, abstracts, conference and symposia proceedings, expert informants, and journal handsearching in the English language.
SELECTION CRITERIA: Randomized controlled trials which compared the effects of prophylactic surfactant administration to surfactant treatment of established respiratory distress syndrome in premature infants were included in the analysis.
DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including the incidence of pneumothorax, pulmonary interstitial emphysema, patent ductus arteriosus, necrotizing enterocolitis, intraventricular hemorrhage (any grade and severe intraventricular hemorrhage), bronchopulmonary dysplasia, mortality, bronchopulmonary dysplasia or death, and retinopathy of prematurity were excerpted from the reports of the clinical trials by the reviewers. Data analysis was done in accordance with the standards of the Cochrane Neonatal Review Group.
MAIN RESULTS: The majority of included studies noted an initial improvement in the respiratory status and a decrease in the incidence of respiratory distress syndrome in infants who received prophylactic surfactant. The meta-analysis supports a decrease in the incidence of pneumothorax, a decrease in the incidence of pulmonary interstitial emphysema, a decrease in the incidence of mortality and a decrease in the incidence of bronchopulmonary dysplasia or death associated with prophylactic administration of surfactant. No significant untoward effects of prophylactic surfactant administration are noted.
REVIEWER'S CONCLUSIONS: Prophylactic surfactant administration to infants judged to be at risk of developing respiratory distress syndrome (intubated infants less than 30-32 weeks gestation) has been demonstrated to improve clinical outcome. Infants who receive prophylactic surfactant have a decreased incidence of pneumothorax, a decreased incidence of pulmonary interstitial emphysema and a decreased incidence of mortality. However, it remains unclear exactly which criteria should be used to judge "at risk" infants who would require prophylactic surfactant administration.
Authors:
R F Soll; C J Morley
Related Documents :
7491219 - Partial deficiency of surfactant protein b in an infant with chronic lung disease.
19490659 - Cost-utility analysis of palivizumab in italy: results from a simulation model in the p...
8542149 - Surfactant subfractions during nosocomial infection in ventilated preterm human neonates.
18394099 - Nasal respiratory support in premature infants: short-term physiological effects and co...
8057989 - Surfactant therapy in respiratory distress syndrome--the first local experience.
22985299 - Infant reminders alter sympathetic reactivity and reduce couple hostility at the transi...
20609279 - Do newly formed word representations encode non-criterial information?
21752749 - Late preterm birth: can be reduced.
2361419 - Trigeminal airstream stimulation. maturation-related cardiac and respiratory responses ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2000  
Date Detail:
Created Date:  2000-07-06     Completed Date:  2000-07-06     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  CD000510     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, University of Vermont College of Medicine, A-121 Medical Alumni Building, Burlington, Vermont 05405-0068, USA. rsoll@salus.med.uvm.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Infant, Newborn
Infant, Premature
Pulmonary Surfactants / therapeutic use*
Respiratory Distress Syndrome, Newborn / prevention & control*
Chemical
Reg. No./Substance:
0/Pulmonary Surfactants
Comments/Corrections
Update In:
Cochrane Database Syst Rev. 2001;(2):CD000510   [PMID:  11405966 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Umbilical artery catheters in the newborn: effects of catheter design (end vs side hole).
Next Document:  Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants.